This post was originally published on this site
https://i-invdn-com.akamaized.net/news/LYNXNPEC0L0PD_M.jpg
Biomarin Pharma announced earnings per share of $0.44 on revenue of $502.1M. Analysts polled by Investing.com anticipated EPS of $0.04 on revenue of $468.56M. That with comparison to EPS of $-0.32 on revenue of $400.7M in the same period a year before. Biomarin Pharma had reported EPS of $0.08 on revenue of $454.4M in the previous quarter. Analysts are expecting EPS of $0.03 and revenue of $476.96M in the upcoming quarter.
Biomarin Pharma shares are up 12.02% from the beginning of the year , still down 4.91% from its 52 week high of $99.60 set on April 27. They are outperforming the Nasdaq (NASDAQ:NDAQ) which is down 1.38% year to date.
Biomarin Pharma’s report follows an earnings beat by J&J on April 14, who reported EPS of $2.3 on revenue of $20.69B, compared to forecasts EPS of $2.02 on revenue of $19.73B.
Pfizer had beat expectations on Tuesday with first quarter EPS of $0.8 on revenue of $12.03B, compared to forecast for EPS of $0.7 on revenue of $11.34B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
